Patterns and preferences of antidiabetic drug use in Turkish patients with type 2 diabetes – A nationwide cross-sectional study (TEMD treatment study). (January 2021)

• Record Type: Journal Article
• Authors: Haymana, Cem; Sonmez, Alper; Demirci, Ibrahim; Fidan Yaylalı, Guzin; Nuhoglu, Irfan; Sancak, Seda; Yilmaz, Murat; Altuntas, Yuksel; Dinccag, Nevin; Sabuncu, Tevfik; Bayram, Fahri; Satman, Ilhan
• Is Part Of: Diabetes research and clinical practice. Volume 171(2021)
• Publication Date: 2021-01
• Subjects: Type 2 diabetes -- Oral antidiabetics -- Insulin -- Diabetic complications -- Complex treatment regimens; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2020.108556
• Languages: English
• ISSNs: 0168-8227

Abstract

Abstract: Aims: The treatment preferences in type 2 diabetes (T2DM) are affected by multiple factors. This survey aims to find out the profiles of the utilization of antidiabetics and their determinants. Methods: The nationwide, multicenter TEMD survey consecutively enrolled patients with T2DM (n = 4678). Medications including oral antidiabetics (OAD) and injectable regimens were recorded. Multiple injectable regimens with or without OADs were defined as complex treatments. Results: A total of 4678 patients with T2DM (mean age: 58.5 ± 10.4 years, 59% female) were enrolled. More than half of patients (n = 2372; 50.7%) were using injectable regimens with or without OADs, and others (n = 2306, 49.3%) were using only OADs. The most common OADs were metformin (93.5%), secretagogues (40.1%), and DPP-4 inhibitors (37.2%). The rates of the use of basal, basal-bolus and premix insulin were 26.5%, 39.5% and 22.4%, respectively. Patients using OADs achieved better glycemia, blood pressure and weight control (p < 0.001 for all) but poorer LDL-C control (p < 0.001). The independent associates of complex treatments were diabetes duration, obesity, eGFR, glycated haemoglobin, macro and microvascular complications, education level, and self-reported hypoglycemia. Conclusion: This study is the first nationwide report to show that almost half of the patients with T2DM are using injectable regimens in Turkey.